Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.76 million.

GUIDANCE:

Halozyme Therapeutics sees FY2017 revenue of $115-130 million, versus the consensus of $132.6 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.